Kowa Research Institute, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.kowaus.com
Clinical Trials
74
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (73 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT06525311
- Locations
- πΊπΈ
Arizona Liver Health, Chandler, Arizona, United States
πΊπΈSouthern California Research Center, Inc, Coronado, California, United States
πΊπΈIndiana University School of Medicine - Indianapolis, Indianapolis, Indiana, United States
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: K-808 (Dose A)Drug: K-808 (Dose B)Drug: Placebo
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT06247735
- Locations
- πΊπΈ
UA Thomas D. Boyer Liver Institute, Tucson, Arizona, United States
πΊπΈSouthern California Research Center - Coronado, Coronado, California, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05826353
- Locations
- πΊπΈ
Keck Hospital of USC, Los Angeles, California, United States
πΊπΈMacy Eye Center, Los Angeles, California, United States
πΊπΈByers Eye Institute at Stanford, Palo Alto, California, United States
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT05795699
- Locations
- πΊπΈ
Keck Hospital of USC, Los Angeles, California, United States
πΊπΈMacy Eye Center, Los Angeles, California, United States
πΊπΈJules Stein Eye Institute, Los Angeles, California, United States
Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05722262
- Locations
- πΊπΈ
PPD - Austin Research Unit, Austin, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next